Research shows exosomal miR-122-3p influences liver disease progression by targeting FGFR4, suggesting treatment potential.
Exosomal miR-122-3p drives the progression of nonalcoholic fatty liver disease by promoting lipid accumulation, oxidative stress, and suppression of AMPK signaling, primarily through targeting FGFR4. These results identify the miR-122-3p/FGFR4 axis as a potential therapeutic target for treating this condition.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: